immunities through the interaction between dendritic cells (DCs)and NKT cells. In addition to
the direct anti-tumor response of activated NKT cells, we found an adjuvant effect of alfa-galacto-
sylceramide (alfa-GalCer) in mice upon intravenous administration of antigen plus alfa-GalCer.
We are studying the process of activation of adaptive immunity, i.e. the mechanism of antitumor
T cellimmunity mediated by augmented innate immunity, and have conducted investigations of
adequate tumor antigen delivery systems.
Our goal is to develop novel therapies for cancers employing a strategy to establish adaptive
antitumor immunity. Since it is often difficult to evaluate NKT cell function in patients with
malignancies due to the reduced numbers of NKT cells, we have attempted to develop
an approach to evaluate the functions of NKT cells and antigen presenting cells (APCs)
in cancer patients to understand the pathologic status of cancer disease.
◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇ RIKEN Yokohama Institute Research Center for Allergy and Immunology Research Unit for Cellular Immunotherapy PHONE:+81-45-503-7063 FAX:+81-45-503-7061 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa,230-0045, Japan ◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇